Evernorth $200/month OOP cap (opt-in plans only) Employers who have opted in to broader weight-loss GLP-1 coverage can offer members an Evernorth $200/month out-of-pocket cap for Wegovy, launched May 21, 2025
The distribution of individual scores illustrates a consistent downward shift across participants, reflecting improvements across multiple behavioural domains captured by the CARS assessment
For 175 years, we have worked to make a difference for all who rely on us
Thank you Unicorn Staff, for all your support Shelby MorgantePosted on YelpErilia V.I went in for a consultation and had a great experience with Talia
What they're saying: "The sheer cost of these medications is a huge barrier to access," Dr
evaluated retatrutide a once-weekly injectable agent targeting GLP-1, GIP, and glucagon receptors simultaneously across multiple doses in adults with obesity or overweight without type 2 diabetes